September 9, 2024 – Goldea Capital

The Keg Royalties Income Fund announces September 2024 cash distribution

Written by Customer Service on September 9, 2024. Posted in Dividend Reports And Estimates.

VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) today announced that its September 2024 distribution of $0.0946 per unit has been declared and is payable to unitholders of record as at September 21, 2024. The September 2024 distribution will be paid on September 30, 2024. The Fund is a limited purpose, open-ended trust established under the laws of the Province of Ontario that, through The Keg Rights Limited Partnership, a subsidiary of the Fund, owns certain trademarks and other related intellectual property used by Keg Restaurants Ltd. (“KRL”). In exchange for use of those trademarks, KRL pays the Fund a royalty of 4% of gross sales of Keg restaurants included in the royalty pool. With approximately 10,000 employees, over 100 restaurants and annual system...

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

Written by Customer Service on September 9, 2024. Posted in Public Companies.

LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding a clinical trial of MN-166 (ibudilast) in the treatment of Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS study has been selected for a poster presentation at the 35th International Symposium on ALS / MND to be held December 6-8, 2024 in Montreal, Canada. The poster presentation will be presented by lead Principal Investigator of this clinical trial, Björn Oskarsson, MD, FAAN Associate Professor of Neurology at Jacksonville, FL, Director of ALS, Center of Excellence. The presentation details are as follows: Paper Number: 302 Paper Status: Accepted as Poster Title: COMBAT-ALS...

CVG Announces Participation in the Barrington Research Fall Investment Conference

Written by Customer Service on September 9, 2024. Posted in Public Companies.

NEW ALBANY, Ohio, Sept. 09, 2024 (GLOBE NEWSWIRE) — CVG (NASDAQ: CVGI) announced today that James Ray, President and Chief Executive Officer and Andy Cheung, Executive Vice President and Chief Financial Officer, will meet with investors registered at the Barrington Research Virtual Fall Investment Conference on September 12, 2024. A link to the presentation materials to be used in the meetings will be accessible through the investor section of the Company’s website at cvgrp.com. For further information, please contact CVGI@alpha-ir.com About CVG At CVG, we deliver real solutions to complex design, engineering and manufacturing problems while creating positive change for our customers, industries, and communities we serve. Information about the Company and its products is available on the internet at www.cvgrp.com. Investor Relations...

Abaxx Files Early Warning Report with Respect to MineHub

Written by Customer Service on September 9, 2024. Posted in Public Companies.

TORONTO, Sept. 09, 2024 (GLOBE NEWSWIRE) — Abaxx Technologies Inc., (CBOE: ABXX) (OTCQX: ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, indirect majority shareholder of Abaxx Singapore Pte Ltd. (“Abaxx Singapore”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announces that it has filed an early warning report in respect of MineHub Technologies Inc. (“MineHub”). On September 9, 2024, pursuant to a share exchange agreement (“SEA”) between Abaxx and MineHub dated July 31, 2024, Abaxx completed a second tranche closing (the “Second Tranche Closing”) and acquired 4,166,666 common shares of MineHub (the “MineHub Shares”). Immediately prior to the Second Tranche Closing,...

Woodward Appoints Ron Charles as Chief Human Resources Officer

Written by Customer Service on September 9, 2024. Posted in Public Companies.

Woodward Appoints Ron Charles as Chief Human Resources Officer Ron Charles joins Woodward as CHRO FORT COLLINS, Colo., Sept. 09, 2024 (GLOBE NEWSWIRE) — Woodward (NASDAQ: WWD), a leader in aerospace and industrial energy control solutions, today announced the appointment of Ron Charles as its Executive Vice President and Chief Human Resources Officer, effective September 9. In this role, he will lead the company’s overall human resources function, including organizational capability, member experience, talent management, total rewards, and diversity, inclusion and belonging, as well as communications and brand. He will be instrumental in advancing Woodward’s efforts to build its talent powerhouse and create a great place to work. As an Executive Vice President and member of the Woodward Executive Leadership Team, Charles...

UPDATE – Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Written by Customer Service on September 9, 2024. Posted in Public Companies.

DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will deliver an in-person presentation at the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY. Details are as follows: H.C. Wainwright 26th Annual Global Investment Conference Date: September 10, 2024 Time: 9am ET Location: Holmes II, Lotte New York Palace Hotel Webcast: click here The webcast will also be archived on Aprea’s corporate website. Management are also available for one-on-one meetings with institutional investors. To request a meeting, please contact...

Centerra Gold Provides Notice of Release and Conference Call for the Thompson Creek Feasibility Study Results and Strategic Plan for the US Molybdenum Operations

Written by Customer Service on September 9, 2024. Posted in Public Companies.

TORONTO, Sept. 09, 2024 (GLOBE NEWSWIRE) — Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG) (NYSE: CGAU) will release the strategic plan for its US molybdenum operations, including results from the Thompson Creek feasibility study and Langeloth Metallurgical Facility commercial optimization plan, after the market closes on Thursday, September 12, 2024. The Company will host a conference call and webcast to discuss the release on Friday, September 13, 2024, at 9:00 a.m. Eastern Time. Details for the conference call and webcast are included below. Webcast Participants can access the webcast at the following link. An archive of the webcast will be available for until end of day December 13, 2024. Conference Call Participants can register for the conference call at the following registration link. Upon registering, you...

Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer

Written by Customer Service on September 9, 2024. Posted in Public Companies.

Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared to chemotherapy WCLC presentation also reviews data on overall survival, progression-free survival and response rate among patients who added chemotherapy to Libtayo following disease progression TARRYTOWN, N.Y., Sept. 09, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced five-year results from the final pre-specified overall survival (OS) analysis of the Phase 3 EMPOWER-Lung 1 trial, which evaluated Libtayo® (cemiplimab) monotherapy versus chemotherapy as a first-line treatment for adults with advanced non-small cell lung cancer (NSCLC) with ≥50% PD-L1 expression and no EGFR, ALK or ROS1 aberrations. The late-breaking...

Phillips Edison & Company Announces Pricing of Offering of $350 Million Aggregate Principal Amount of 4.950% Senior Unsecured Notes Due 2035

Written by Customer Service on September 9, 2024. Posted in Public Companies.

CINCINNATI, Sept. 09, 2024 (GLOBE NEWSWIRE) — Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced that its operating partnership, Phillips Edison Grocery Center Operating Partnership I, L.P. (the “Operating Partnership”), has priced a public offering of $350 million aggregate principal amount of 4.950% senior unsecured notes due 2035 (the “Notes”). The Notes were priced at 98.458% of the principal amount and will mature on January 15, 2035. The offering is expected to settle on September 12, 2024, subject to the satisfaction of customary closing conditions. The notes will be fully and unconditionally guaranteed by PECO. The Operating Partnership intends to use the net proceeds...

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)

Written by Customer Service on September 9, 2024. Posted in Public Companies.

If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children The submission of neffy 1 mg sNDA follows FDA approval on August 9, 2024, of neffy (2 mg) for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh 30 kg (66 lbs.) or greater SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today the submission of a supplemental New Drug Application (sNDA) for neffy® 1 mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in children who weigh 15 to 30 kg (33-66 lbs.). Pharmacokinetic...

Day: September 9, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice